MinervaX raises upsized EUR 47.4M (USD 57M) Series B to advance its novel Group B Streptococcus vaccine through mid-stage clinical trials

On the back of highly promising Phase Ib data, MinervaX has raised financing from leading investors to accelerate development of its novel vaccine through the end of Phase II trials and preparations for Phase III pivotal trials Sanofi Ventures, Wellingt... Biopharmaceuticals, Venture Capital MinervaX, Group B Streptococcus
Source: HSMN NewsFeed - Category: Pharmaceuticals Source Type: news